FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen
containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic
colorectal cancer